Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Shalini Sharp sold 24,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $71.20, for a total transaction of $1,708,800.00. Following the completion of the transaction, the chief financial officer now directly owns 69,387 shares of the company’s stock, valued at approximately $4,940,354.40. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Shalini Sharp also recently made the following trade(s):

  • On Wednesday, October 19th, Shalini Sharp sold 12,000 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $61.40, for a total transaction of $736,800.00.

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) opened at 82.06 on Monday. The company’s 50-day moving average is $66.41 and its 200-day moving average is $63.72. The company’s market capitalization is $3.35 billion. Ultragenyx Pharmaceutical Inc. has a 12-month low of $46.52 and a 12-month high of $117.12.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($1.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.53) by $0.11. During the same quarter in the previous year, the company posted ($1.03) EPS. Analysts predict that Ultragenyx Pharmaceutical Inc. will post ($6.14) EPS for the current year.

Insider Buying and Selling by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

A number of equities research analysts have recently issued reports on the stock. Jefferies Group reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Sunday, July 17th. Canaccord Genuity set a $120.00 price objective on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research note on Friday, October 21st. Wedbush reaffirmed an “outperform” rating and issued a $92.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 8th. Cowen and Company reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, August 9th. Finally, Zacks Investment Research cut shares of Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Friday. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $94.70.

Large investors have recently added to or reduced their stakes in the stock. CAM Group Holding A S boosted its stake in Ultragenyx Pharmaceutical by 52.5% in the second quarter. CAM Group Holding A S now owns 61,000 shares of the biopharmaceutical company’s stock valued at $2,984,000 after buying an additional 21,000 shares during the last quarter. ClariVest Asset Management LLC boosted its stake in Ultragenyx Pharmaceutical by 15.7% in the second quarter. ClariVest Asset Management LLC now owns 12,552 shares of the biopharmaceutical company’s stock valued at $613,000 after buying an additional 1,700 shares during the last quarter. Alps Advisors Inc. boosted its stake in Ultragenyx Pharmaceutical by 25.5% in the second quarter. Alps Advisors Inc. now owns 54,816 shares of the biopharmaceutical company’s stock valued at $2,681,000 after buying an additional 11,142 shares during the last quarter. American Century Companies Inc. boosted its stake in Ultragenyx Pharmaceutical by 10.3% in the second quarter. American Century Companies Inc. now owns 41,566 shares of the biopharmaceutical company’s stock valued at $2,033,000 after buying an additional 3,874 shares during the last quarter. Finally, Creative Planning boosted its stake in Ultragenyx Pharmaceutical by 16,700.0% in the second quarter. Creative Planning now owns 4,200 shares of the biopharmaceutical company’s stock valued at $205,000 after buying an additional 4,175 shares during the last quarter. Hedge funds and other institutional investors own 93.14% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

5 Day Chart for NASDAQ:RARE

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.